CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

Published Date: 18 Mar 2024

For CLL/SLL patients who are refractory or have relapsed, lixocabtagene maraleucel (Breyanzi) has a new indication.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Extracellular matrix pathway emerges as treatment target for pediatric cancer

2.

The New Canadian Guidelines for Drinking at High Risk, AUD.

3.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

4.

A paper strip test might enable the early detection of cancer.

5.

In leukemia, allogeneic HCT is beneficial following primary induction failure.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot